OBJECTIVE: Metastasis is thought to be governed partially by induction of epithelial-mesenchymal transition. Combination of proteasome and histone deacetylase inhibitors has shown significant promise, but no studies have investigated this in esophageal cancer. This study investigated effects of vorinostat (histone deacetylase inhibitor) and bortezomib (proteasome inhibitor) on esophageal cancer epithelial-mesenchymal transition. METHODS: Three-dimensional tumor spheroids mimicking tumor architecture were created with esophageal squamous and adenocarcinoma cancer cells. Cells were treated with tumor necrosis factor alpha (to simulate proinflammatory tumor milieu) and transforming growth factor beta (cytokine critical for induction of epithelial-mesenchymal transition). Tumor models were then treated with vorinostat, bortezomib, or both. Cytotoxic assays assessed cell death. Messenger RNA and protein expressions of metastasis suppressor genes were assessed. After treatment, Boyden chamber invasion assays were performed. RESULTS: Combined therapy resulted in 3.7-fold decrease in adenocarcinoma cell invasion (P = .002) and 2.8-fold decrease in squamous cell invasion (P = .003). Three-dimensional invasion assays demonstrated significant decrease in epithelial-mesenchymal transition after combined therapy. Quantitative reverse transcriptase polymerase chain reaction and Western blot analyses revealed robust rescue of E-cadherin transcription and protein expression after combined therapy. Importantly, inhibition of the E-cadherin gene resulted in abolition of the salutary benefits of combined therapy, highlighting the importance of this metastasis suppressor gene in the epithelial-mesenchymal transition process. CONCLUSIONS: Combined vorinostat and bortezomib therapy significantly decreased esophageal cancer epithelial-mesenchymal transition. This combined therapeutic effect on esophageal cancer epithelial-mesenchymal transition was associated with upregulation of E-cadherin protein expression. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
OBJECTIVE: Metastasis is thought to be governed partially by induction of epithelial-mesenchymal transition. Combination of proteasome and histone deacetylase inhibitors has shown significant promise, but no studies have investigated this in esophageal cancer. This study investigated effects of vorinostat (histone deacetylase inhibitor) and bortezomib (proteasome inhibitor) on esophageal cancer epithelial-mesenchymal transition. METHODS: Three-dimensional tumor spheroids mimicking tumor architecture were created with esophageal squamous and adenocarcinoma cancer cells. Cells were treated with tumor necrosis factor alpha (to simulate proinflammatory tumor milieu) and transforming growth factor beta (cytokine critical for induction of epithelial-mesenchymal transition). Tumor models were then treated with vorinostat, bortezomib, or both. Cytotoxic assays assessed cell death. Messenger RNA and protein expressions of metastasis suppressor genes were assessed. After treatment, Boyden chamber invasion assays were performed. RESULTS: Combined therapy resulted in 3.7-fold decrease in adenocarcinoma cell invasion (P = .002) and 2.8-fold decrease in squamous cell invasion (P = .003). Three-dimensional invasion assays demonstrated significant decrease in epithelial-mesenchymal transition after combined therapy. Quantitative reverse transcriptase polymerase chain reaction and Western blot analyses revealed robust rescue of E-cadherin transcription and protein expression after combined therapy. Importantly, inhibition of the E-cadherin gene resulted in abolition of the salutary benefits of combined therapy, highlighting the importance of this metastasis suppressor gene in the epithelial-mesenchymal transition process. CONCLUSIONS: Combined vorinostat and bortezomib therapy significantly decreased esophageal cancer epithelial-mesenchymal transition. This combined therapeutic effect on esophageal cancer epithelial-mesenchymal transition was associated with upregulation of E-cadherin protein expression. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Authors: J B Sunwoo; Z Chen; G Dong; N Yeh; C Crowl Bancroft; E Sausville; J Adams; P Elliott; C Van Waes Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: Marty W Mayo; Chadrick E Denlinger; Robert M Broad; Fan Yeung; Eugene T Reilly; Yang Shi; David R Jones Journal: J Biol Chem Date: 2003-03-20 Impact factor: 5.157
Authors: Wm Kevin Kelly; Victoria M Richon; Owen O'Connor; Tracy Curley; Barbara MacGregor-Curtelli; William Tong; Mark Klang; Lawrence Schwartz; Stacie Richardson; Eddie Rosa; Marija Drobnjak; Carlos Cordon-Cordo; Judy H Chiao; Richard Rifkind; Paul A Marks; Howard Scher Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: Johannes von Burstin; Stefan Eser; Mariel C Paul; Barbara Seidler; Martina Brandl; Marlena Messer; Alexander von Werder; Annegret Schmidt; Jörg Mages; Philipp Pagel; Angelika Schnieke; Roland M Schmid; Günter Schneider; Dieter Saur Journal: Gastroenterology Date: 2009-04-09 Impact factor: 22.682
Authors: Xu Han; Sun Yan; Zhang Weijie; Wang Feng; Wang Liuxing; Li Mengquan; Fan Qingxia Journal: Cancer Gene Ther Date: 2014-01-24 Impact factor: 5.987
Authors: Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944
Authors: Michael Millward; Timothy Price; Amanda Townsend; Christopher Sweeney; Andrew Spencer; Shawgi Sukumaran; Angie Longenecker; Lonnie Lee; Ana Lay; Girish Sharma; Robert M Gemmill; Harry A Drabkin; G Kenneth Lloyd; Saskia T C Neuteboom; David J McConkey; Michael A Palladino; Matthew A Spear Journal: Invest New Drugs Date: 2011-11-12 Impact factor: 3.850
Authors: David S Liu; Sanne J M Hoefnagel; Oliver M Fisher; Kausilia K Krishnadath; Karen G Montgomery; Rita A Busuttil; Andrew J Colebatch; Matthew Read; Cuong P Duong; Wayne A Phillips; Nicholas J Clemons Journal: Oncotarget Date: 2016-12-13